Castagnoli, L., Franceschini, A., Cancila, V., Dugo, M., Bigliardi, M., Chiodoni, C., . . . Pupa, S. M. CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. BMC.
Chicago Style (17th ed.) CitationCastagnoli, Lorenzo, et al. CD36 Enrichment in HER2-positive Mesenchymal Stem Cells Drives Therapy Refractoriness in Breast Cancer. BMC.
MLA (9th ed.) CitationCastagnoli, Lorenzo, et al. CD36 Enrichment in HER2-positive Mesenchymal Stem Cells Drives Therapy Refractoriness in Breast Cancer. BMC.
Warning: These citations may not always be 100% accurate.